Hrt Financial LP Glaukos Corp Transaction History

Hrt Financial LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$59.53 - $85.11 $855,267 - $1.22 Million	14,367 New	14,367 $1.14 Million
Q2 2023 Aug 11, 2023	SELL	$45.44 - $71.21 $152,133 - $238,411	-3,348 Reduced 39.41%	5,147 $366,000
Q1 2023 May 12, 2023	BUY	$43.88 - $52.48 $372,760 - $445,817	8,495 New	8,495 $425,000
Q2 2022 Aug 12, 2022	BUY	$34.86 - $63.77 $83,210 - $152,218	2,387 Added 44.52%	7,749 $351,000
Q1 2022 May 16, 2022	BUY	$44.33 - $57.82 $237,697 - $310,030	5,362 New	5,362 $310,000
Q4 2021 Feb 14, 2022	SELL	$40.27 - $56.99 $716,886 - $1.01 Million	-17,802 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$47.43 - $84.23 $234,493 - $416,433	4,944 Added 38.45%	17,802 $857,000
Q2 2021 Aug 16, 2021	BUY	$73.06 - $97.7 $739,951 - $989,505	10,128 Added 370.99%	12,858 $1.09 Million
Q1 2021 May 17, 2021	BUY	$70.43 - $97.42 $192,273 - $265,956	2,730 New	2,730 $229,000
Q1 2019 May 14, 2019	SELL	$50.75 - $80.54 $271,766 - $431,291	-5,355 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$52.18 - $67.93 $279,423 - $363,765	5,355 New	5,355 $300,000

341

46.8M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.12B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.